Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 40.36
-0.66 (-1.61%)
Aug 13, 2026, 5:29 PM CET
Hansa Biopharma AB Market Cap
Hansa Biopharma AB has a market cap or net worth of 4.17 billion as of August 13, 2026. Its market cap has increased by 75.88% in one year.
Market Cap
4.17B
Enterprise Value
4.66B
Revenue
189.46M
Ranking
n/a
PE Ratio
n/a
Stock Price
40.36
ChartMarket Cap Chart
Since April 24, 2008, Hansa Biopharma AB's market cap has increased from 30.71M to 4.17B, an increase of 13,491.71%. That is a compound annual growth rate of 30.76%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2026 | 4.17B | 19.38% |
| Dec 30, 2025 | 3.50B | 31.53% |
| Dec 30, 2024 | 2.66B | 93.47% |
| Dec 29, 2023 | 1.37B | -46.77% |
| Dec 30, 2022 | 2.58B | -34.64% |
| Dec 30, 2021 | 3.95B | -63.06% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Egetis Therapeutics AB | 3.36B |
| Vicore Pharma Holding AB | 3.31B |
| Saniona AB | 1.86B |
| Flerie AB | 1.76B |
| BioInvent International AB | 1.57B |
| Genovis AB (publ.) | 1.34B |
| Medivir AB | 1.13B |
| SynAct Pharma AB | 1.08B |